Switzerland’s Roche (ROG: SIX) has filed to expand the label for Xofluza (baloxavir marboxil) in the USA.
The US regulator will consider an application for approval to market the oral therapy as a single-dose treatment for people at high risk of complications from the flu. A decision is expected by November 4, 2019.
Roche’s subsidiary Genentech secured US approval for Xofluza in 2018, following one of the worst flu seasons in many years. The approval currently covers acute, uncomplicated flu for certain people over 12 years of age.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze